Page last updated: 2024-12-05

isomaltose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Isomaltose is a disaccharide composed of two glucose molecules linked by an α(1→6) glycosidic bond. It is a naturally occurring sugar found in various foods, including starch, honey, and malt. Isomaltose is not easily digested by humans due to the α(1→6) linkage, which cannot be hydrolyzed by the human digestive enzymes. However, some bacteria in the gut possess the necessary enzymes to break down isomaltose. Isomaltose is often used as a sweetener in food products. It is also used in the production of pharmaceuticals and other industrial products. Research on isomaltose focuses on its potential as a prebiotic, its role in the gut microbiome, and its impact on blood glucose levels. Isomaltose is also studied for its potential to improve insulin sensitivity and reduce the risk of developing type 2 diabetes.'

Cross-References

ID SourceID
PubMed CID439193
CHEMBL ID66675
CHEBI ID28189
SCHEMBL ID1782423
MeSH IDM0011768
PubMed CID10357
MeSH IDM0011768

Synonyms (41)

Synonym
alpha-d-glcp-(1->6)-d-glcp
alpha-d-glucosyl-(1->6)-d-glucose
6-o-alpha-d-glucopyranosyl-d-glucopyranose
alpha-d-glc-(1->6)-d-glc
alpha-d-glucopyranosyl-(1->6)-d-glucopyranose
CHEBI:28189 ,
(3r,4s,5s,6r)-6-[[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2,3,4,5-tetrol
C00252
isomaltose, ~98% (tlc)
MLS001333223
smr000857202
MLS001333224
CHEMBL66675
(3r,4s,5s,6r)-6-[[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol
d-isomaltose
alpha-1,6-glucobiose
I0231
HMS2236B05
SCHEMBL1782423
(3r,4s,5s,6r)-6-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-2,3,4,5-tetrol
AKOS026749917
DLRVVLDZNNYCBX-RTPHMHGBSA-N
Q28487684
(3r,4s,5s,6r)-6-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)methyl)tetrahydro-2h-pyran-2,3,4,5-tetraol
alpha-d-glucopyranose-(1->6)-d-glucopyranose
alpha-d-glcp-(1-6)-d-glcp
alpha-d-glucopyranosyl-(1-6)-d-glucopyranose
6-o--d-glucopyranosyl-d-glucose; d-isomaltose
isomaltose ,
499-40-1
brachiose
alpha-d-glucopyranose-(1->6)-beta-d-glucopyranose
6-o-alpha-d-glucopyranosyl-beta-d-glucopyranose
beta-isomaltose
84B72DF1-D9A0-4577-8DAB-9289F6B6ADA5
(2r,3r,4s,5s,6r)-6-[[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol
6-o-a-d-glucopyranosyl-d-glucose
6-o-alpha-delta-glucopyranosyl-delta-glucose
Q2409080
37169-69-0
(2r,3r,4s,5s,6r)-6-((((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)methyl)tetrahydro-2h-pyran-2,3,4,5-tetraol

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Both formulae were well accepted without differences in time of crying, flatulence, stool characteristics and the occurrence of adverse events."( Effects of a Follow-On Formula Containing Isomaltulose (Palatinose™) on Metabolic Response, Acceptance, Tolerance and Safety in Infants: A Randomized-Controlled Trial.
Demmelmair, H; Fleddermann, M; Holdt, L; Koletzko, B; Rauh-Pfeiffer, A; Teupser, D, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" We hypothesised that the reduced digestion and absorption rate of isomaltulose would result in lower glycaemic and insulinaemic responses when compared with the ingestion of sucrose, leading to greater postprandial fat oxidation rates."( Reduced glycaemic and insulinaemic responses following isomaltulose ingestion: implications for postprandial substrate use.
Blaak, EE; Brouns, F; Ijzerman, TH; van Can, JG; van Loon, LJ, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
"Improved insulin sensitivity was significantly related to exercise dose in a graded dose-response relationship."( Exercise dose and insulin sensitivity: relevance for diabetes prevention.
Allison, KF; Amati, F; Dubé, JJ; Goodpaster, BH; Rousson, V, 2012
)
0.38
"This study identifies a graded dose-response relationship between exercise dose and improvements in insulin sensitivity."( Exercise dose and insulin sensitivity: relevance for diabetes prevention.
Allison, KF; Amati, F; Dubé, JJ; Goodpaster, BH; Rousson, V, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
en:Snacks, en:Sweet snacks, en:Confectioneries, en:Candies, en:Hard candies1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
glycosylglucose
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Digestion and absorption1724
Digestion1223
Digestion of dietary carbohydrate611
Disease1278231
Diseases of metabolism69121
Diseases of carbohydrate metabolism1229
Intestinal saccharidase deficiencies16

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency4.46680.044717.8581100.0000AID485294
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency0.70790.707936.904389.1251AID504333
serine-protein kinase ATM isoform aHomo sapiens (human)Potency39.81070.707925.111941.2351AID485349
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency125.89203.548119.542744.6684AID743266
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID91575Inhibitory activity against HIV-1 integrase at 25 uM; ND denotes No data2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Developing a dynamic pharmacophore model for HIV-1 integrase.
AID91439Inhibitory activity against HIV-1 integrase at 1 mM2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Developing a dynamic pharmacophore model for HIV-1 integrase.
AID91440Inhibitory activity against HIV-1 integrase at 200 uM2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Developing a dynamic pharmacophore model for HIV-1 integrase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (371)

TimeframeStudies, This Drug (%)All Drugs %
pre-199078 (21.02)18.7374
1990's54 (14.56)18.2507
2000's95 (25.61)29.6817
2010's99 (26.68)24.3611
2020's45 (12.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.77 (24.57)
Research Supply Index6.04 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index90.42 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials47 (12.60%)5.53%
Reviews0 (0.00%)6.00%
Reviews17 (4.56%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies3 (0.80%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
Other306 (82.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]